Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMICUS THERAPEUTICS, INC.

(FOLD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Amicus Therapeutics : Arya Sciences Acquisition Corp to Create Genetic Medicine Company Caritas Therapeutics

09/29/2021 | 08:16am EST


ę MT Newswires 2021
All news about AMICUS THERAPEUTICS, INC.
04:28aEuropean Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applica..
AQ
12/03Health Care Stocks Rise in Premarket Friday
MT
12/03Amicus Therapeutics Says EMA Accepts its Marketing Authorization Applications for AT-GA..
MT
12/03AMICUS THERAPEUTICS : European Medicines Agency Validates Amicus Therapeutics Marketing Au..
PU
12/03AMICUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/03European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applica..
GL
12/03European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applica..
CI
11/24Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Confer..
GL
11/22AMICUS THERAPEUTICS : Long-term efficacy with migalastat in ERT-naïve and ERT-experience p..
PU
11/22AMICUS THERAPEUTICS : Incidence and prevalence of newborn, paediatric and adolescent patie..
PU
More news
Analyst Recommendations on AMICUS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 308 M - -
Net income 2021 -203 M - -
Net cash 2021 145 M - -
P/E ratio 2021 -13,9x
Yield 2021 -
Capitalization 2 912 M 2 912 M -
EV / Sales 2021 8,97x
EV / Sales 2022 6,94x
Nbr of Employees 483
Free-Float 90,0%
Chart AMICUS THERAPEUTICS, INC.
Duration : Period :
Amicus Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMICUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 10,45 $
Average target price 17,11 $
Spread / Average Target 63,7%
EPS Revisions
Managers and Directors
John Francis Crowley Chairman & Chief Executive Officer
Bradley Lewis Campbell President, Chief Operating Officer & Director
Daphne E. Quimi Chief Financial Officer
Jill Weimer Chief Science Officer
Patrik S. Florencio Senior VP, Global Chief Compliance & Risk Officer
Sector and Competitors
1st jan.Capi. (M$)
AMICUS THERAPEUTICS, INC.-53.49%2 912
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-42.48%24 298